4 results
to investigate the safety and efficacy of idarucizumab in reversing the anticoagulation effect of dabigatran, in patients who have uncontrolled bleeding or require emergency surgery or invasive procedures.
The current study is set up to validate the working mechanism of the current design of the FemFlow.
Primary Objective: This study is set up to validate the patient comfort of the current design of the FemFlow. For the validation of the patient comfort, the FemFlow will be rated on:Comfort during insertion Comfort of an alien object in the bladder…
The current trial aims to asses the safety of this combination in a phase I trial with olaparib dose escalation during two cycles of 177Lu-DOTATATE in salvage setting in patients with advanced GEP NET, progressive after initial PRRT.